The treatment candidate RXC007 demonstrated promising efficacy in easing fibrosis, or scarring, in mouse models of idiopathic pulmonary fibrosis (IPF) and other scarring-related conditions. In healthy human volunteers participating in a recently-completed Phase 1 trial, RXC007 displayed a good safety and pharmacological profile. Now, Redx Pharma, the company…
IPF Treatment RXC007 Shows Promise in Easing Scarring in Mice
While working on today’s column, I considered writing about my birthday on Oct. 4. Then, a topic came to me quite unexpectedly. On Monday, Sept. 26, I had to go to the hospital. Since the pandemic began, I’ve been careful to avoid large crowds in enclosed spaces and to…
Dosing has begun in healthy volunteers in a Phase 1 clinical trial evaluating the safety and pharmacological properties of LASN01, an experimental therapy for pulmonary fibrosis and other diseases characterized by excessive tissue scarring, or fibrosis. “The initiation of this trial is an important milestone for Lassen and continues…
Bellerophon Therapeutics has gotten the green light to cut by about half the number of patients who may enter REBUILD, its ongoing Phase 3 trial of INOpulse (inhaled nitric oxide) for the treatment of pulmonary hypertension linked to pulmonary fibrosis. The downsizing may help the company complete the…
As a child in elementary school, I once earned the top grade on a project about inspirational people in Canada. I was fascinated by what made them inspirational to others, whether it was a marathon for cancer research by the late Terry Fox or a wheelchair race for disability…
“While walking on the beach yesterday, I realized how I’m feeling about PF, in general, is like the tide. There are times like now that I’m riding the high tide, full of energy about taking on PF activities (hosting PF get-togethers, participating in fundraising walks). Then the water is gone,…
Piceatannol, a natural compound with antioxidant and anti-inflammatory properties, eased the signs and symptoms of pulmonary fibrosis (PF) in mice, a study reported. According to its researchers, these findings indicate that piceatannol could be a promising treatment candidate for PF. The study, “Piceatannol-mediated JAK2/STAT3 signaling pathway inhibition…
Algernon Pharmaceuticals has filed for orphan drug status for NP-120 (ifenprodil), an experimental oral medicine for patients with idiopathic pulmonary fibrosis (IPF) who have persistent, hard-to-treat cough. “The FDA has a standard response time of 90 days to requests for orphan designation, and so we should know by…
I’ve spent much of my working life conducting investigations. As a special agent for the Air Force Office of Special Investigations and in a second career providing security and investigative services under contract to the federal government, the cases all had similar objectives. Simply stated, any investigation needs to answer…
Treatment with Haduvio (nalbuphine extended-release tablets) significantly reduced coughing for people with idiopathic pulmonary fibrosis (IPF), according to top-line data from the Phase 2 CANAL trial. “It is very promising to see such a significant reduction in chronic cough in IPF patients with [Haduvio],” Peter Dicpinigaitis, MD, a professor…
